Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (NCT06662162)
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD. Participants will: * Undergo an initial loading regimen, followed by 7 maintenance over the course of 11 months. * Participants will return monthly through Month 14 (3 months post-last treatment) for evaluation and monitoring.
Who can join: Review the eligibility criteria below.
Location: Retina Consultants San Diego — Poway, California
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Retina Consultants San Diego — Poway, California
- Retina Consultants PC — Manchester, Connecticut
- University Retina & Macula Associates — Lemont, Illinois
- Sierra Eye Associates — Reno, Nevada
- Retina Associates of Cleveland — Beachwood, Ohio
- Texas Retina Associates — Fort Worth, Texas
- Tyler Retina Research Insitute — Tyler, Texas
- Cerulea — East Melbourne, Victoria
- Auckland Eye Limited — Remuera, Auckland
- Queens University Belfast / Belfast City Hospital — Belfast,
- King's College Hospital — London,
- London North West University Healthcare — Middlesex,
- Sunderland Eye Infirmary — Sunderland,
📞 Contact the Study Coordinator
Phone: (408) 440-7049
Email: mmundy@i-lumen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Age-Related Macular Degeneration
- Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD — Loma Linda, California
- National Eye Institute Biorepository for Retinal Diseases — Bethesda, Maryland
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders — Springfield, Illinois
- Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration — San Francisco, California
- Effects of Goji vs. Fiber on Macular Degeneration — Sacramento, California
Explore by condition: All Age-Related Macular Degeneration clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.